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Abstract
Background: Our goal was to identify gene signatures predictive of response to preoperative systemic chemotherapy (PST)
with epirubicin/cyclophosphamide (EC) in patients with primary breast cancer.
Methods: Needle biopsies were obtained pre-treatment from 83 patients with breast cancer and mRNA was profiled on
Affymetrix HG-U133A arrays. Response ranged from pathologically confirmed complete remission (pCR), to partial remission
(PR), to stable or progressive disease, "No Change" (NC). A primary analysis was performed in breast tissue samples from 56
patients and 5 normal healthy individuals as a training cohort for predictive marker identification. Gene signatures identifying
individuals most likely to respond completely to PST-EC were extracted by combining several statistical methods and filtering
criteria. In order to optimize prediction of non responding tumors Student's t-test and Wilcoxon test were also applied. An
independent cohort of 27 patients was used to challenge the predictive signatures. A k-Nearest neighbor algorithm as well as
two independent linear partial least squares determinant analysis (PLS-DA) models based on the training cohort were selected
for classification of the test samples. The average specificity of these predictions was greater than 74% for pCR, 100% for PR
and greater than 62% for NC. All three classification models could identify all pCR cases.
Results: The differential expression of 59 genes in the training and the test cohort demonstrated capability to predict response
to PST-EC treatment. Based on the training cohort a classifier was constructed following a decision tree.
First, a transcriptional profile capable to distinguish cancerous from normal tissue was identified. Then, a "favorable outcome
signature" (31 genes) and a "poor outcome signature" (26 genes) were extracted from the cancer specific signatures. This
stepwise implementation could predict pCR and distinguish between NC and PR in a subsequent set of patients. Both PLS-DA
models were implemented to discriminate all three response classes in one step.
Conclusion: In this study signatures were identified capable to predict clinical outcome in an independent set of primary breast
cancer patients undergoing PST-EC.
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Introduction
Breast cancer is the most common neoplasia of women
being diagnosed in approximately 211,000 women annu-
ally in the United States. In spite of earlier detection and
improved treatment, it remains the second leading cause
of cancer-related death in the United States and in other
developed countries [1]. The genetic background of
patients and the tumor's genetic and epigenetic anomalies
create, in combination, molecularly distinct subtypes aris-
ing from distinct cell types within the ductal epithelium
[2,3]. This genetic complexity underlies the clinical heter-
ogeneity of breast cancer limiting a rational selection of
treatment tailored to individual patient/tumor
characteristics.
Standard therapeutic decision-making (i.e.., NIH; St. Gal-
len consensus) rely on several clinicopathological factors
such as patients' age, tumor stage, grade, size, nodal status
as well as hormone, and growth receptor status. The anal-
ysis of single molecular markers such as ki-67 and ERBB2
can also contribute to the therapeutic decision making.
Although all of these factors have been correlated to
patients' survival in general, the same prognostic profile
often results in dissimilar clinical outcomes in individual
patients. Thus, conventional prognostic factors provide
insufficient information to evaluate the heterogeneity of
this disease and to make treatment more effective for indi-
vidual patients.
One problem faced by present cancer therapy is the over-
treatment of patients with chemotherapy, which is associ-
ated with severe toxicity and increasing healthcare spend-
ing without clear survival benefit over untreated controls
[4,5]. Because of the lack of adequate predictive markers
(i.e., ER, HER2/neu), nearly all patients receive routinely
standard treatment in spite of grim changes of deriving
any benefit. Therefore, the identification of molecular
markers predictive of patients' responsiveness to treat-
ment is becoming a central focus of translational research.
Micro array technology offers insights about the simulta-
neous expression of thousands of genes providing global
information about the transcriptional program associated
with specific cellular or tissue conditions. This provides a
high-throughput screening tool for the identification of
molecular patterns of cancerous cell possibly associated
with their sensitivity to therapy [6-9]. This strategy yielded
significant contributions by dissecting beyond his-
topathologic features the molecular aspects of breast can-
cers, their association with lymph-nodal spread,
metastatization and overall survival.
An important and so far seldom explored utilization of
micro array technology is the identification of signatures
predictive of responsiveness to chemotherapy. To get clear
correlation between chemotherapeutic success and pre
treatment gene expression we needed to rely in a model
where chemotherapy is given before surgical resection so
that its outcome could be evaluated. Beside the most com-
mon postoperative (adjuvant) chemotherapy, preopera-
tive systemic therapy (PST) has been recently proposed for
early-stage breast cancer. PST, uses cytotoxic drugs as the
first modality of treatment allowing in vivo monitoring of
the therapeutic responsiveness of a primary tumor over a
given time period (e.g., 4 months). PST is offered preoper-
atively to patients with either large inoperable breast can-
cers or to patients interested in breast conserving surgery
[10-16]. PST in general does not offer a survival advantage
over standard adjuvant treatment but does identify those
patients (up to 20%) with tumors reacting with a com-
plete remission to the drug [17,18]. Complete tumor
remission, as confirmed by pathological examination, is
often associated with prolonged disease free survival [19-
22]. Additionally, PST can reduce the growth rate of resid-
ual distant micrometastases compared with classical adju-
vant therapy [17].
By predicting which subset of tumors may respond to PST
transcriptional profiling of pre-treatment samples could
represent a powerful tool for patient selection.
Patients, Materials and methods
Patients
This study was performed in collaboration with the Insti-
tute of Chemical Oncology, University of Düsseldorf, Ger-
many, and Bayer Healthcare AG, Diagnostic Research,
Leverkusen, Germany. All patients were recruited at the
Interdisciplinary Breast Center IBC, City Hospital Düssel-
dorf. Patients signed an informed consent before any pro-
cedure. Study eligibility criteria required that participants
presented with not previously treated primary breast can-
cer to be treated preoperatively.
Samples of primary breast carcinomas were collected
between May 1999 and March 2003 from patients sub-
jected to PST treatment with epirubicine/cyclophospha-
mide (EC). Since in several cases treatment modifications
occurred or full pathological confirmation of response
status was not conclusive not all samples were studied.
Quality of samples related to delays in processing also
limited the number of samples studied. In the end, a total
of 56 tumor samples were identified from comparable
treatment groups and were studied for marker discovery
together with five normal breast samples excised from
patient with benign pathology. Additionally, tumor sam-
ples removed from 27 patients treated with EC-based PST
between December 2002 and September 2003 were ana-
lyzed as a second independent validation cohort. EC con-
sisted of epirubicin 90 mg m2 per day 1 in a short i.v.
infusion, and cyclophosphamide 600 mg m2 per day 1 inJournal of Translational Medicine 2005, 3:32 http://www.translational-medicine.com/content/3/1/32
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Table 1: Clinical and molecular data on breast cancer patients (training set).
Case Response Tumor 
reduction
,%
Histology pre Age ER PR BCL2 P53 KI67,% CerbB2 Grading
BC1492 NC 0 invasive lobular 50 0 0 0 1 28 0 2
BC1426 NC 0 invasive ductal + intraductal(40%) 62 1 1 400 0 2 1+ to 2+ 1 a. 2
BC1257 NC 0 invasive lobular 69 1 1 180 0 16 1+ to 2+ 2
BC1176 NC 0 invasive lobular a. tubular-lobular 47 1 1 130 0 7 0 2
BC1092 NC 0 invasive lobular a. ductal 66 1 1 0 0 10 0 2
BC1050 NC 0 invasive tubular-lobular; multifocal 60 1 1 60 0 3 0 2
BC1034 NC 0 intraductal a. invasive 43 1 1 0 0 2 0 2
BC1044 NC 0 invasive tubular-lobular 68 1 1 70 0 6 0 1
BC1466 pCR 100 invasive ductal a. intraductal(30%) 57 0 0 0 0 26 3+ 2
BC1255 pCR 100 invasive lobular 57 1 0 60 1 26 0 2
BC1254 pCR 100 medullary 62 0 0 0 0 70 1+ 3
BC1180 pCR 100 invasive lobular a. ductal 32 0 0 0 0 20 1+ 2
BC1159 pCR 100 invasive lobular a. ductal 40 0 0 70 0 70 1+ to 2+ 2
BC1042 pCR 100 non-typical medullary a. intraductal (bifocal) 38 0 0 10 0 35 0 3
BC1032 pCR 100 invasive lobular a. ductal 58 0 0 0 0 15 3+ 2
BC1443 PR/CR 94 invasive lobular a. ductal 61 1 0 10 0 30 3+ 2
BC1167 PR 0 invasive lobular 71 1 1 400 0 8 0 2
BC1162 PR 0 invasive lobular 66 1 1 70 0 7 1+ 2
BC1143 PR 0 invasive ductal a. intraductal(5%) 54 1 1 210 0 17 1+ 2
BC1138 PR 0 invasive lobular; multifocal 57 1 1 80 0 13 1+ 2
BC1100 PR 0 invasive tubular-lobular 55 1 1 140 0 4 0 1
BC1040 PR 0 invasive ductal 40 1 1 294 0 28 0 2
BC1170 PR 0 invasive lobular a. ductal bifocal 67 1 0 210 0 4 2+ to 3+ 2
BC1140 PR 10 left: invasive lobular 73 1 1 180 0 14 0 2
BC1418 PR 12 left:bifocal invasive tubular-lobular 57 1 0 300 0 7 2+ 1
BC1420 PR 15 invasive ductal a. lobular; multifocal 63 1 1 400 0 3 2+ 2
BC1491 PR 18 invasive lobular 64 1 1 300 0 7 0 2
BC1515 PR 20 invasive ductal 64 1 1 300 1 10 0 2
BC1445 PR 20 right:invasive lobular; bifocal 64 1 0 160 0 15 1+ to 2+ 2
BC1036 PR 24 invasive ductal 58 1 1 392 0 15 0 2
BC1308 PR 25 invasive lobular; multifocal 74 0 0 0 0 16 2+ 2
BC1133 PR 25 invasive ductal 53 0 0 294 0 50 0 3
BC1259 PR 32 invasive ductal a. lobular (Herd1) a. invasive 
ductal (Herd2)
59 1 0 300 0 16 2+ to 3+ 2
BC1498 PR 33 invasive ductal; bifocal 62 1 0 15 0 19 3+ 3
BJ_40613 PR 35 invasive ductal 61 1 1 100 0 4 2+ 2
BC1166 PR 35 invasive ductal a. lobular 45 1 1 140 0 14 1+ to 2+ 2
BC1142 PR 35 invasive lobular; bifocal 53 1 1 20 0 18 1+ 2
BC1422 PR 40 invasive ductal a. lobular; multifocal 53 1 1 360 0 2 2+ 2
BC1132 PR 40 invasive ductal 41 1 1 30 1 18 2+ 3
BC1096 PR 40 invasive ductal 46 1 1 294 0 13 0 2
BC1129 PR 42 invasive tubular-lobular 52 0 0 0 0 15 2+ 2
BC1130 PR 45 invasive lobular 42 1 1 140 0 NA 0 2
BC1131 PR 45 invasive ductal (pulmonal, ossar) 63 1 0 300 0 45 0 2
BC1256 PR 50 invasive lobular 60 0 0 0 1 17 1+ 2
BC1446 PR 50 invasive lobular; bifocal 53 1 1 140 0 35 1+ 2
BC1116 PR 53 invasive lobular 49 1 1 180 0 3 0 2
BC1415 PR 55 invasive lobular; multifocal 53 0 0 15 1 40 0 2
BC1141 PR 55 invasive lobular 52 1 1 500 0 20 0 2
BC1495 PR 60 invasive tubular a. intraductal (10%); bifocal 58 1 0 300 0 2 0 2
BC1497 PR 75 invasive lobular 42 1 1 300 0 5 2+ 2
BC1160 PR 75 invasive lobular 47 0 1 30 0 35 0 2
BC1038 PR 75 invasive ductal 35 1 1 294 0 30 0 2
BC1095 PR 85 invasive tubular-lobular 60 1 0 294 0 1 0 1Journal of Translational Medicine 2005, 3:32 http://www.translational-medicine.com/content/3/1/32
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a short i.v. infusion. Four cycles of EC were administrated
14 days apart. Some patients received additionally
Tamoxifen, Femara or seldom Zoladex for 4–5 weeks after
EC course and before surgery. All tumor samples were col-
lected as needle biopsies of primary tumors prior to any
treatment. The biopsies were obtained under local
anesthesia using Bard® MAGNUM™ Biopsy Instrument (C.
R. Bard, Inc., Covington, U. S.) with Bard®  Magnum
biopsy needles (BIP GmbH, Tuerkenfeld, Germany) fol-
lowing ultrasound guidance. Samples were collected fol-
lowing routine conditions for pathological diagnosis
following institutional review board guidelines. Patholog-
ical examination was carried out for all tumor samples by
the same pathologist at the Interdisciplinary Breast Center
IBC. The remainders of the samples were flash-frozen.
After PST, all patients underwent a radical mastectomy or
a lumpectomy and axillary node dissection at the discre-
tion of the treating breast surgeon. Postoperative chemo-
therapy was administrated at the discretion of the treating
medical oncologist. Breast or chest wall irradiation was
administrated in selected patients. In addition, all women
with ER-positive tumors were started on tamoxifen ther-
apy. A detailed list of all samples and clinical data is pre-
sented in Tables 1 and 2 (see also Additional files 1 and
2). Additionally, five normal breast samples from reduc-
tion mammoplasties were analyzed.
Immunohistochemistry (IHC)
Hematoxilin/eosin-stained sections from tumor speci-
mens were examined to assess the relative amounts of
tumor cells, benign epithelium, stroma, and lymphocytes.
Standard clinical parameters, such as estrogen receptor-α
(ER), progesterone receptor (PgR), proliferation marker
(ki-67), tumor suppressor p53, regulator of apoptosis
Bcl2, protooncogene cerbB2/HER2neu, epidermal growth
factor receptor (EGFR) were assessed according to routine
bio- and/or immunohistochemical methods.
Immunohistochemical staining was performed on 5-µm
paraffin sections. Sections were deparaffinized in xylene
and re-hydrated. Epitope retrieval was performed by heat
induction in Target Retrival Solution pH6.1 (DAKO,
DakoCytomation GmbH, Hamburg, Germany). Tissues
were blocked for endogenous peroxidase in a 0.3% H2O2
solution for 15 min. Monoclonal antibodies (ERa: ER1D5
DAKO 1:35, PR: PGR636 DAKO 1:50, bcl-2: Clone 124
1:200 DAKO, EGFR: 31G7 CYTOMED 1:20, cerb2/Her-2/
neu polyclonal DAKO 1:250, and ki67 (MIB-1) DAKO
1:200) were used for specific epitope detection. The
ChemMate DAKO peroxidase/DAB Detection Kit was
used for linking and staining. Slides were counterstained
with methyl green and coverslipped with entelan. Histo-
logic scores were calculated by multiplying color intensity
(range 0 to 5) with proportion of cells staining positive.
Response Criteria
Response to the treatment followed the Unio Internation-
ale Contra Cancrum criteria [23]. pCR (pathological diag-
nosis based complete responders), was defined as absence
of invasive carcinoma in the breast by the examining
pathologist and lack of lymph nodal involvement. cCR
(clinical complete responders) was defined as clinical
absence of invasive carcinoma of the breast. This parame-
ter was used as a surrogate for pCR in one occasion when
a patient declined post-PST surgical excision. PR (partial
responders) was determined as a reduction in the tumor
mass of both perpendicular dimensions ranging from
10% to 75% of the initially measured tumor size based on
dynamic contrast-enhanced magnetic resonance imaging
or magnetic resonance tomography (MRT), and some-
times on both, MRT and ultrasonography. NC (non-
responders or no change) was defined as an absence of
tumor reduction or an increase in tumor size (stable or
progressive disease). The percent of tumor reduction
(Table 1 and 2) was calculated as a ratio between patho-
logic tumor size [cm] after neoadjuvant chemotherapy at
the time of surgical excision compared to the size of
tumors defined clinically at the time of diagnosis. More
details are available as Additional files 3 and 4 from the
JTM Web page.
RNA Preparation and Microarray Analysis
Total RNA was extracted from cell lysates of ground tissue
and subsequent purification with RNeasy mini spin col-
umns (Qiagen, Hilden, Germany). Subsequent washing
and elution steps were performed according to manufac-
turer's instructions. High-quality RNA was obtained as
suggested by well-preserved 28S and 18S ribosomal RNA
bands (present in an approximately 2:1 intensity ratio),
along with A260/A280 ratios between 1.8 and 2.0. Qual-
ity and integrity of total RNA was tested with a
Bioanalyzer 2100 (Agilent Technologies Inc., Palo Alto,
BC1024 PR 88 invasive lobular 59 1 1 70 0 18 0 2
BC1101 PR 75–85 invasive lobular; multifocal 75 1 0 180 0 10 3+ 2
BC1139 PR 89–90 invasive lobular with DCIS parts; multifocal 55 1 1 NA 0 15 NA 1
ER and PgR status were determined by immunohistochemistry. 1 – positive (>7 fmol/mg protein); 0 – negative (<7 fmol/mg protein). HER2/neu 
status: copies of HER2/neu gene. Status of p53 oncogene: 0 - <180 score; 1 - >180 score. NA – not available.
Table 1: Clinical and molecular data on breast cancer patients (training set). (Continued)Journal of Translational Medicine 2005, 3:32 http://www.translational-medicine.com/content/3/1/32
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CA, USA). Gene expression analysis was performed on an
Affymetrix Human Genome U133A GeneChip platform
containing 22,283 probes. Preparation and processing of
labeled and fragmented cRNA targets, hybridization and
scanning procedures were carried according to the manu-
facturer's protocol (Affymetrix, Santa Clara, CA, USA)
[24]. Starting material for labeling consisted of 5 µg of
total RNA from each tumor specimen. Labeling was lim-
ited to one cycle of in vitro transcription. Thus, starting
with 5 µg of total RNA, approximately 50 to 60 µg of
amplified RNA (cRNA) could be generated, which could
be used in multiple microarray experiments. The cRNA
was quantified by Agilent Nano Chip technology and
evaluated for size relative to pure polyadenylated RNA.
Fifteen micrograms of cRNA were subsequently used for
hybridization. After washing and staining arrays were
scanned by Gene Array scanner 2500 (Affymetrix).
Hybridization intensity data were automatically acquired
and processed by Affymetrix Microarray Suite 5.0 soft-
ware. The expression level (average difference) of each
gene was determined by calculating the average of differ-
ences in intensity (perfect match-mismatch) between its
probe pairs as described elsewhere [25]. Scans were
rejected if the scaling factor exceeded 2 or "chip surface
scan" revealed scratches, specks or gradients affecting
overall data quality (Refiner, GeneData AG, Basle,
Switzerland).
Quantitative Real-Time PCR.
Aliquots of total RNA used for GeneChip expression anal-
ysis were used for quantitative RT-PCR with an ABI PRISM
7900 Sequence Detection System (Applied Biosystems,
Foster City, CA, USA). cDNA for PCR amplification was
generated by oligo dT primed reverse transcription
(Superscript First Strand System, Invitrogen Corporation,
Carlsbad, CA, USA) including DNAse I treatment. Primers
and probes were designed with the Primer Express soft-
ware (Applied Biosystems, Foster City, CA, USA) and
spanned the same gene region of the respective Affymetrix
probe set. Labeled oligonucleotides were obtained from
Eurogentec s.a. (Liege, Belgium). Absolute copy numbers
were normalized according to GAPDH as a reference gene.
The primer/probes were prepared by mixing 25 µl of 100
µM stock solution "upper primer", 25 µl of 100 µM stock
Table 2: Clinical and molecular data on breast cancer patients (test set).
Case Response Tumor 
reduction
, %
Histology pre Age ER PR BCL2 P53 KI67, % CerbB2 Grading
BC1843 NC 0 invasive ductal; bifocal 63 1 1 200 0 18 1+ 2
BC1850 NC 0 invasive lobular 58 1 1 300 0 6 0 2
BC1862 NC 0 invasive lobular a. intraductal 59 1 1 196 0 11 1+ 2
BC1871 NC 10 invasive lobular 46 1 1 140 1 24 0 2
BC1869 pCR 100 invasive ductal 60 0 0 0 0 50 0 3
BC1864 pCR 100 invasive a. intraductal (DCIS; 80%) 55 0 0 0 0 50 0 2
BC1421 pCR 100 invasive lobular 71 0 0 0 1 26 0 2
BC1870 cCR 100 invasive ductal 43 0 0 0 1 35 1+ to 2+ 2
BC18611 PR 40 invasive ductal a. intraductal (very small) 36 0 0 0 0 35 0 3
BC1879 PR 47 invasive ductal 37 1 1 500 0 45 0 2
BC1866 PR 40 invasive lobular 52 1 1 300 1 24 2+ to 3+ 2
BC1837 PR 90 invasive ductal 69 0 0 0 0 48 1+ 3
BC1838 PR 80 invasive lobular 59 1 0 50 0 20 1+ to 2+ 2
BC1842 PR 92 invasive ductal 68 0 0 0 0 29 1+ 2
BC1834 PR 0 invasive ductal a. intraductal (very small) 60 1 1 30 0 10 3+ 3
BC1858 PR 0 invasive lobular 62 1 1 140 0 16 1+ 2
BC1880 PR 40 invasive ductal and intraductal (5%) 62 1 1 200 0 26 0 2
BC1881 PR 62 invasive ductal 72 0 0 0 1 22 0 2
BC1849 PR 22 invasive ductal 52 1 0 200 0 19 3+ 2
BC1839 PR 10 invasive ductal 62 0 0 45 1 16 0 2
BC1513 PR 33 invasive lobular; multicentr. 60 1 1 300 0 10 0 2
BC1877 PR/NC 50 left: invasive lobular a. CLIS Type-A 53 1 1 300 0 6 1+ 2
BC1853 PR/NC 0 invasive lobular 51 1 1 400 0 14 0 2
BC1448 PR 68 medullary invasive 50 1 1 30 1 38 3+ 3
BC1134 PR/NC 5 invasive lobular 73 1 0 70 0 14 0 2
BC18402 PR 25 invasive ductal 45 1 1 60 0 35 2+ to 3+ 3
BC1848 PR 85 invasive ductal; bifocal 42 1 0 500 1 28 3+ 2
Note: 1 – This patient has received 4 × EC and, additionally, 4 × Taxol; 2 – this patient has received 3 × EC and, additionally, 3 × FEC.Journal of Translational Medicine 2005, 3:32 http://www.translational-medicine.com/content/3/1/32
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solution "lower primer" plus 12,5 µl of the 100 µM stock
solution TaqMan-probe (FAM/TAMRA) and adjusted to
500  µl with H2O (Primer/probe-mix). PCR reactions
using cDNA generated from 1.5 ng total RNA were per-
formed in duplicates in a volume of 10 µl. This included
TaqMan universal Mix (Eurogentec s.a.) according to
manufacturer's protocol in a 384-well format and 1 µl of
the P&P mix. Thermal cycler parameters were 2 min at
50°C, 10 min at 95°C and 40 cycles, each consisting of a
15 s denaturation step at 95°C and a 1 min annealing/
extension step at 60°C. Relative abundance of a gene tran-
script was calculated either by the ∆∆Ct method or by
arbitrarily defined RNA copy number estimates at a Ct =
24 as 106 copies. Subsequent analysis included normaliza-
tion steps such as median centering and per gene median
division.
Data Filtering
Fifty-six primary breast cancer and 5 non cancerous breast
tissue samples were analyzed as a training set for marker
discovery. Raw data was acquired using Microsuite 5.0
software from Affymetrix and normalized following the
standard practice of scaling the average of all gene signal
intensities to a common arbitrary value (TGT = 100).
Gene expression data were stored including P-value, as
generated by Microsuite 5.0 software, for quality assess-
ment of individual measurements for each transcript. The
data-file was imported into Expressionist Analyst software
package (GeneData AG) for further statistical analysis. To
enhance quality we excluded gene probe sets for the fol-
lowing reasons. Fifty-nine probe sets corresponding to
hybridization reference (housekeeping genes, etc.) as
identified by Affymetrix were removed with the exception
of GAPDH and β -actin, for which a 3' biased probe set was
included. One hundred genes, whose expression levels are
routinely used for normalization of the HG-U133A and
HG-U133B GeneChip versions [26], were also removed
from the analysis. These genes reflect a very homogenous
expression pattern among several human tissues and
could therefor be categorized as "house keeping" genes.
Genes with potentially high levels of noise (81 probe sets)
frequently observed with low absolute expression values
(below 30 relative signal units (RSU) in all experiments)
were also removed. The remaining genes were preproc-
essed to eliminate those (3,196) whose signal intensities
were not significantly different (P > 0.04) from their back-
ground levels and thus labeled as "Absent" by MicroSuite
5.0. To apply a higher stringency to the data, we elimi-
nated genes whose significance levels (P < 0.04) were only
reached in 10% of the breast cancer samples (3,841 probe
sets). Data for the remaining 15,006 probe sets were used
for the subsequent analysis.
Statistical Analysis
For the analysis we applied a similar strategy to the one
applied by Wang E. and colleagues [27] to predict
immune responsiveness of melanoma metastases. Genes
differentially expressed by lesions characterized by differ-
ent responsiveness to PST were identified with the non-
parametric Wilcoxon rank sum test, two-sample
independent Students't-test and Welch test. Probes were
ranked in order of significance (SUM-Rank test) combin-
ing the results of these tests using as a cut-off P-value <
0.05 and fold change between groups >2. The Kruskal-
Wallis and ANOVA tests were applied when two distinct
groups (i.e. pCR vs NC) with extreme response patterns
where studied in the presence of a third intermediate
group (PR). All statistical tests were two-tailed. Principal
components analysis (PCA) and hierarchical clustering
were applied for data display and structural analysis and
in certain steps for dimensional (probe set) reduction. All
these different tools were used as implemented in the
GeneData Expressionist Analyst software package and
were only modified by selection of starting parameters
and appropriate distance weight matrices. Additionally,
partial least squares discriminant analysis for multivariate
data (PLS-DA) with SIMCA-P software (Umetrics, AB,
Umea, Sweden) was used.
Results
Preliminary analysis about ER status and inflammation
Previous studies [28-31] reported that patients with nega-
tive estrogen receptor (ER) status respond better to PST
compared to those with a positive one. In addition, PgR1
gene expression may affect outcome. Furthermore,
patients with ER-negative tumors suffer shorter disease-
free and overall survival [32-34]. ER status is also associ-
ated with a characteristic gene expression profile inde-
pendent of other clinical/pathological parameters
[35,36]. Therefore, we separately studied genes known to
be associated with ER signaling. We analyzed previously
the expression profile of breast cancer in two patient
cohorts with positive and negative ER status (not part of
this study). The complete gene list and expression data
within the two cohorts is available (Additional file 5). We
identified 828 Affymetrix probe sets by ANOVA and t-test
(P < 0.005) with a median fold change of 1.2 or above.
Analysis of the 828 ER-related signatures in the 56 tumors
from the present study correlated well with ER-α status by
immunohistochemistry. To avoid the influence on clini-
cal outcome of ER-specific signatures and identify alterna-
tive, ER-independent predictors of response and survival,
these genes were excluded
We also excluded genes related to immune function since
we could not predict the effect that the heterogeneity of
immune infiltrates might bear on the transcriptional pro-
file of individual lesions. Immune genes (1,025) wereJournal of Translational Medicine 2005, 3:32 http://www.translational-medicine.com/content/3/1/32
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identified and excluded. The complete list of excluded
genes is available (Additional file 6). Many of the
excluded genes are members of immunoglobulin fami-
lies. The final data set contained 13,145 probe sets.
Although there is currently plenty of interest about the
impact of immunity as a predictor of clinical outcome,
this was beyond the purpose of this work and will be con-
sidered in a subsequent manuscript.
Determination of predictor genes
Starting with the training cohort, we built response sub-
classes based on the post surgical clinicopathological
examination. Eight of the 56 training cases experienced a
pCR and eight progressed (NC). To identify the most pre-
dictive genes for each class we implemented a comparison
schedule for the training set as follows:
(I) PR vs. NC (n = 40 vs. 8); (II) pCR vs. PR (n = 8 vs. 40),
and (III) pCR vs. NC (n = 8 vs. 8). These comparisons were
carried out by non-parametric t-test, Welch, Wilcoxon,
Kolmogorov-Smirnov tests using the Expressionist Ana-
lyst software (GeneData AG). Differentially expressed
genes were considered those reaching a significance cut off
P-value of < 0.05 in all tests; 2,301 were identified. Addi-
tional restrictions were then applied (at least 2-fold
change of median expression level and average expression
more than 30 RSU (relative signal units) in all three
groups) resulting in only 1,512 probe sets useful for fur-
ther analyses.
For the "three-group tests" (pCR vs. PR vs. NC) statistical
significance was measured with the Kruskal-Wallis and
one-way ANOVA tests with a cut off P-value of < 0.05
identifying 414 probe sets. Overlap of the gene lists
(1,512 probe sets and 414 probe sets) by Venn diagram
analysis qualified 397 probe sets. This high stringency
potentially eliminated genes of interest but decreased the
false discovery rates of random selected genes at P-value
cut off <0.05. PCA using all predefined tissue classes: non
cancerous breast tissue pCR, cCR, PR and NC was applied
to the 397 probe sets. Separation of pCR and cCR tumors
on the one side and NC samples on the other was defined
by 2 most distinguishing components. We applied a cut-
off on the correlation matrix of the PCA and filtered genes
Table 3: Comparison of predicted and pathologic response in test set.
Case Tumor reduction,% Response, pathologic Predicted response 






BC1843 0 NC NC NC PR
BC1850 0 NC NC NC NC
BC1862 0 NC NC NC PR
B C 1 8 7 1 1 0 N CN CN CP R
BC1869 100 pCR CR CR CR
BC1864 100 pCR CR CR CR
BC1421 100 pCR CR CR CR
BC1870 100 cCR CR CR CR
BC1861 40 PR PR CR CR
BC1879 47 PR PR NC NC
BC1866 40 PR PR CR CR
B C 1 8 3 7 9 0 P RC RC RC R
BC1838 80 PR PR NC NC
B C 1 8 4 2 9 2P RP RP RP R
BC1834 0 PR PR PR CR
BC1858 0 PR NC NC NC
B C 1 8 8 0 4 0P RP RP RP R
BC1881 62 PR NC PR PR
BC1849 22 PR NC NC PR
BC1839 10 PR NC NC PR
BC1513 33 PR PR NC PR
BC1877 50 PR PR NC NC
BC1853 0 NC NC NC NC
B C 1 4 4 8 6 8 P RC RC RC R
BC1134 5 NC NC NC NC
B C 1 8 4 0 2 5 P RN CN CN C
B C 1 8 4 8 8 5 P RC RC RC R
Note: complete pathologic response shown as CR when predicted.Journal of Translational Medicine 2005, 3:32 http://www.translational-medicine.com/content/3/1/32
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at < -0.4 and > 0.4. This sorted out 325 by eliminating 72
probe sets.
We then excluded from the remaining 325 genes those
known to be specifically expressed in blood vessels, adi-
pocytes, and muscle tissues based on differential expres-
sion profiling of tumor cells and normal cells after their
separation by laser capture microdissecction or by com-
paring breast tumor's gene expression profiles with
expression profiles of normal blood vessels, adipose and
muscle tissue samples reducing the number of genes by
61. The list of the excluded 61 genes is available (Addi-
tional file 7). Rank ordering of the remaining 264 genes'
significance was determined by SUM-Rank test for all
samples and compared to the original 13,145 genes.
In addition, two classifier genes were identified (FHL1
and CLDN5) highly discriminative between most "nor-
mal" tissue samples and all breast cancer samples ana-
lyzed. Whereas these genes are expressed at very high
levels in normal breast tissue their low level expression
was rarely detected in malignant breast samples. We com-
bined these 2 genes with 57 most discriminative genes
from 264 filtered probe sets (Additional file 8). Such
combination allows simple and fast separation of normal
tissue samples from malignant ones, which might be use-
ful for routine clinical diagnostics. A detailed table con-
taining raw data for 59 genes and 83 tumors is available
as supplemental information (Additional files 9 and 10).
Validation on independent cases
The determined classifiers could be subdivided into three
categories: those genes/probe sets capable to distinguish
between (a) normal breast and breast cancer tissues (2
genes, FHL1 and CLDN5), (b) pCR or cCR from unfavora-
ble outcomes (PR or NC) (31 probe sets or "favorable
response signature"), and (c) NC and PR (26 probe sets or
"poor response signature"). We expected that both signa-
tures, favorable and poor, would separate the two most
extreme classes pCR and NC and effectively recognize the
respective expression patterns. These classifiers were chal-
lenged against samples from an independent test cohort
(n = 27; 4 pCR, 4 NC, 19 PR; see Table 2 or Additional file
2). Classification was performed by k-NN (k = 3) follow-
ing a three step decision tree based on the 59 genes listed
above. All 27 tumor samples were correctly qualified as
cancerous tissues using the two-gene signature (FHL1 and
CLDN5). Whit the "favorable response signature" a group
of 8 tumor samples was classified as CR or PR. Finally, the
rest of the tumors were classified as NC or PR by the "poor
response signature". There were four potentially wrong
classified cases. Results of classification for the test cohort
Table 4: Summarized results of validation on the test cohort.
Predicted response k-NN Predicted response PLS-DA; 
model 1
Predicted response PLS-DA; 
model 2
predicted CR 7 9 10
other 20 18 17
predicted PR 9 4 9
other 18 23 18
predicted NC 11 14 8
other 16 13 19
Sensitivity CR 100 100 100
Specificity CR 87 78 74
PPV 57 44 40
NPV 100 100 100
Sensitivity PR 53 24 35
Specificity PR 100 100 100
PPV 100 100 67
NPV 56 43 39
Sensitivity NC 100 100 50
Specificity NC 76 62 76
PPV 55 43 38
NPV 100 100 84Journal of Translational Medicine 2005, 3:32 http://www.translational-medicine.com/content/3/1/32
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are shown in Table 3. Summarized results of validation, as
well as sensitivity, specificity positive and negative predic-
tive values (PPV and NPV, respectively) for each class are
shown in Table 4.
PCA and Hierarchical Clustering
A PCA plot was created displaying the position of each
tumor sample from training and test cohorts (83 tumors)
using three main Eigenvectors (Fig. 1A). The PCA was
performed with the set of 57 response predictive genes for
illustration purpose. The two most disparate response
groups (pCR and NC) are clearly separated with the excep-
tion of one NC case, BC1492, which clusters with pCR
tumors. This plot is consistent with k-NN cross-validation
results for training cohort, which defined that NC case
BC1492 as complete response. Hierarchical clustering of
all 83 tumors and 57 response predicting genes is shown
in Fig. 1B and 1C: eleven of twelve pCR tumors are organ-
ized in one sub-branch of the sample dendrogram and NC
tumors are placed into the separate dendrogram branch.
Clustering of gene expression data for 57 genes from 83 breast tumors corresponding training and test cohorts Figure 1
Clustering of gene expression data for 57 genes from 83 breast tumors corresponding training and test cohorts. A. PCA analy-
sis of response groups and gene expression. The visualization of high-dimensional data in three-dimensional principal compo-
nents. Individual samples from training and test cohorts are labeled according to three response groups: green and light green – 
pCR; yellow and light yellow – PR; red and light red – NC. The distance between samples reflects their approximate degree of 
correlation. B. Hierarchical clustering presents the clustered samples in columns and the clustered 57 genes in rows. A color 
representation of gene expression levels is shown with the scale on the left side. The 57 genes used fir both clustering methods 
were obtained by multi-step statistical approach, as described in 'A predictor gene set determination' section of Results. C. An 
enlarged version of sample dendrogram, which reflects similarities in their expression profiles.
A B
CJournal of Translational Medicine 2005, 3:32 http://www.translational-medicine.com/content/3/1/32
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Partial least squares discriminant analysis (PLS-DA)
Direct linear discriminant analysis was applied to com-
pare the previous results and test the potential of our first
classifier model. PLS-DA applies well to the large number
of predictors and the multicollineality. Supervised PLS-
DA analysis uses independent (expression levels) and
dependent variables (classes) for class comparison apply-
ing multivariate statistical methods such as soft independ-
ent modeling of class analogy (SIMCA) and partial least
squares modeling with latent variables to allow simulta-
neous analysis of all variables [37-42]. Additionally, PLS-
DA provides a quantitative estimation of the discrimina-
tory power of each descriptor by means of VIP (variable
importance for the projection) parameters. VIP values rep-
resent an appropriate quantitative statistical parameter
ranking descriptors (gene expression values) according to
their ability to discriminate different classes.
PLS-DA was carried out on the original 13,145 probe sets
that passed the QC filtering process in the training cohort.
Although this process may lead to an over parameterized
model with poor prediction properties, it provides a pre-
liminary assessment of the most important discriminative
variables. Two independent models were tested each con-
sisting of two classes: model 1 (class 1 – pCR, class 2 – NC,
and PR cases were excluded); model 2 (class 1 – pCR, class
2 – NC and PR together). The model with three classes
(pCR, NC and PR) demonstrated rather poor prediction
power being strongly dependent on the definition of par-
tial response (Table 1). Possibly the comparison of path-
ological estimates (post treatment) compared to clinical
measurements (pre-treatment) over estimated the tumor
reduction measurements and biased the attribution of
samples as PR rather than NC.
Those variables satisfying the criteria of expression levels
above 60 RSU (as a mean value in at least one of each sam-
ple group, pCR and NC), ratio (pCR/NC) >1.9 or <0.55,
and VIP of >1.9 were retained. Figure 2 shows a scatter
plot of samples from the training set grouped according to
PLS discrimination according to tumor response class using the variables selected by PLS (VIP > 1.9) and ratio (pCR/NC) > 1.9  or < 0.55 Figure 2
PLS discrimination according to tumor response class using the variables selected by PLS (VIP > 1.9) and ratio (pCR/NC) > 1.9 
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the two components for either PLS in model 1 (96 probe
sets; Fig. 2) or in the model 2 (90 probe sets; Fig. 3) after
the second iteration. The numbers next to the symbols are
the sample IDs as detailed in Table 1. It is apparent that
pCR and NC samples are clearly discriminated. However,
the results of permutation tests for both models (data not
shown) demonstrated that both reduced models were still
over-parameterized. Thus, we retained the 20 probe sets
deduced from model 1 and 20 probe sets from model 2
with highest VIP values. In both cases, models performed
much better than expected by chance.
Two groups of selected probe sets were compared and
nine probe sets were found to be represented in both lists,
which were deduced from model 1 and 2. A combined list
containing 31 probe sets was used for model validation
(Table 5) by applying PLS-DA to the second, independent
group of tumors (n = 27; Table 2) to test the discrimina-
tive power of the final gene list. The results are presented
in Table 3. PLS-DA classified partially responding tumors
with good (> 60% tumor shrinkage) or very poor response
to therapy as complete response (e.g., BC1837, BC1848,
BC1448) or no response (e.g., BC1877, BC1134, BC1840)
respectively. This observation indicates that for further
studies the monitoring of tumor shrinkage during PST is
pivotal to correctly judge the final response classification
and it might have been the major limitation of this study.
Both statistical approaches, one that yielded the 59 gene
and PLS-DA were compared and identified 19 genes in
common. PLS-DA alone demonstrated a lower predictive
power compared to the first multi-step analysis combined
with k-NN classification.
Confirmation of expression measurements by real-time 
RT-PCR
Real-time RT-PCR (qPCR) measurement of gene expres-
sion levels on the same RNAs used for GeneChip hybridi-
zation experiments obtained from 32 breast tumors from
training and test cohorts was performed on 46 genes
selected from those presented in Table 3. Primer and
probes were designed in regions within or close to the tar-
get region of the GeneChip oligonucleotides. A Ct value of
24 was empirically considered to represent 106 RNA cop-
ies per well based on spiking experiments. Raw data from
real-time RT-PCR are presented in Supplemental Data on
the Web page, as above, along with Affymetrix Gene-
Chip's data. Relative expression as measured by the
GeneChip was compared with qPCR results adjusting the
median expression of all 46 genes within one sample to
100 relative units. To detect the relative difference in
PLS discrimination according to tumor response class using the variables selected by PLS (VIP > 1.9) and ratio (pCR/NC) > 1.9  or < 0.55 Figure 3
PLS discrimination according to tumor response class using the variables selected by PLS (VIP > 1.9) and ratio (pCR/NC) > 1.9 
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expression between samples for each gene, all measure-
ments were divided by the median expression of this gene.
This median normalization was carried out for both plat-
forms independently. Raw and normalized data for
Affymetrix and TaqMan platforms are shown in Addi-
tional file 11. In order to compare the individual measure-
ments and the relative abundance of each transcript we
preformed hierarchical clustering with the data generated
with the GeneChip system. We performed this clustering
(Fig. 4) with a correlation matrix on the samples as well as
on the genes while the distance measurement was carried
out with an average weight matrix. Once having the clus-
ter of the GeneChip data in place we ordered all samples
and all genes for the qPCR data in the same order as
derived from the previous clustering. This operation
resulted in very similar heat-maps as depicted in Figure 4
Table 5: Top 31 genes extracted from two different models from PLS-DA SIMCA.
Gene Symbol Gene Description Ref. Sequences Unigene ID
 KPNA2




transcriptional regulator homolog RPD3 histone deacetylase 2 similar to yeast RPD3 NM_001527 4557640
PRKAB1 5-AMP-activated protein kinase beta-1, non-catalytic subunit NM_006253 18602783
IMPDH2
inosine monophosphate dehydrogenase (IMPDH2) NM_000884 4504688
YR-29
hypothetical protein clone YR-29 NM_014886 7662676
CD2BP2 CD2 antigen (cytoplasmic tail)-binding protein 2 NM_006110 5174408
 FHL2
heart protein (FHL-2) four and a half LIM domains 2 NM_001450 4503722
DDB2
damage-specific DNA binding protein p48 subunit (DDB2; 48 kD) NM_000107 4557514
ASNS asparagine synthetase NM_001673 4502258
 XPA
XPAC protein xeroderma pigmentosum complementation group A NM_000380 4507936
PLA2G7
LDL-phospholipase A2 phospholipase A2 group VII (platelet-activating factor acetylhydrolase plasma) NM_005084 4826883
BTBD2
BTB (POZ) domain containing 2 hypothetical protein FLJ20386 EST NM_017797 8923361
CCNG1 cyclin G1 clone MGC:6 NM_004060 -
PDHB pyruvate dehydrogenase E1-beta subunit d pyruvate dehydrogenase (lipoamide) beta NM_000925 4505686
MKI67 mki67a (long type)antigen of monoclonal antibody Ki-67 NM_002417 4505188
TNRC15
KIAA0642 protein trinucleotide repeat containing 15 AL_045800 18550089
RPL17 ribosomal protein L17 NM_000985 14591906
GNG12 DKFZp586B0918 (from clone DKFZp586B0918) NM_018841 -
RPL17
ribosomal protein L17 NM_000985 14591906
DKC1
Cbf5p homolog (CBF5) dyskeratosis congenita 1 dyskerin nucleolar protein NM_001363 15011921
DCTN4 dynactin p62 subunit dynactin 4 (p62) NM_016221 14733974
FLJ20273
RNA-binding protein NM_019027 9506670
FLJ11323 hypothetical protein EST NM_018390 8922994
MGC11242 hypothetical protein MGC11242 ESTs NM_024320 13236560
SRR serine racemase Homo sapiens cDNA NM_021947 8922495
ARL3
48c8 ADP-ribosylation factor-like 3 EST NM_004311 4757773
 CCNB2
cyclin B2 NM_004701 10938017
MAD2L1
MAD2 protein MAD2 (mitotic arrest deficient yeast homolog)-like 1 NM_002358 6466452
LIG1
membrane glycoprotein LIG-1d NM_015541 18554950
PMSCL1
polymyositisscleroderma autoantigen 1 (75 kD) EST NM_005033 4826921
 APBB2
amyloid beta (A4) precursor protein-binding, family B NM_173075 18557629
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with an overall correlation of R2 = 0.73. We also per-
formed independent clustering of the qPCR data (Fig. 5),
which resulted in similar correlation trees.
Discussion
The aim of this study was to identify a multigene predictor
of response to EC in a PST. Several recent studies
demonstrated that gene expression profiling can predict
response in the neoadjuvant setting [43-47]. Since the
patient-specificity of such predictors remain questionable
[48], further attempts devoted to the understanding of the
process (es) underlying responsiveness to systemic ther-
apy are of obvious importance.
Primary systemic chemotherapy is often being used to
downstage large and locally advanced breast tumors in
patients prior to surgery. There is increasing evidence that
response and, particularly, complete response to neoadju-
vant chemotherapy predicts improved disease-free and
overall survival [49-51]. Unquestionable, pathological
complete response (pCR) is not a synonym for cure, since
a risk remains for metastatic disease. But such risk is
decreased in association with the down-staging of the
primary tumor and the achievement of a node negative
status confirmed at the time of surgery. Therefore, it is rea-
sonable to suggest that a good response to neoadjuvant
therapy may correspond to survival benefit.
Confirmation of expression measurements by real-time RT-PCR Figure 4
Confirmation of expression measurements by real-time RT-PCR. GeneChip median expression for 46 genes from Table 3 
within one sample was adjusted to 100 RLU. Then, all measurements were median centered for each gene. Hierarchical clus-
tering algorithm was applied to median normalized expression data of 46 genes from 39 tumor samples from training and test 
cohorts. Hierarchical clustering presents the clustered samples in columns and the clustered 46 genes in rows. A color repre-
sentation of gene expression levels is shown with the scale on the left side (pCR represented in green, NC represented in red). 
Clustering of the data was performed according a correlation analysis with an average distance determination. The threshold 
Ct values obtained in real-time RT-PCR were converted into an arbitrary RNA-copy number Ct value of 24, which was then 
empirically settled to 106 RNA copies per well. These measurements were median centered, as for microarray data. All data 
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The role of biological characteristics and/or molecular
markers as predictor of sensitivity to specific treatments
has been extensively studied [52-56]. However, their role
in response prediction remains unclear. Results from dif-
ferent studies are often contradictory and, consequently,
no individual biological marker can be reliably used clin-
ically for prediction of response to chemotherapy [57,58].
The patients analyzed in this study were part of a much
larger cohort (n = 319) receiving treatment with EC-based
PST. We have observed in this patient population that age,
histologic grade, estrogen receptor (ER), progesterone
receptor (PgR), levels of oncogene B-cell leukemia 2
(Bcl2), proliferation-related Ki-67 antigen (ki-67), and
epidermal growth factor receptor (EGFR) expression were
related to response in a univariate analysis, also con-
firmed by Colleoni et al. [33] in preoperative settings.
However, in a multivariate model it was only ki-67 expres-
sion that predicted a better pathological response (P =
0.011), and this factor was linked to the patient's age [59].
Thus, a true predictive marker that could be measured by
routine methods (e.g., IHC) to identify patients likely to
benefit from neo-adjuvant EC remains elusive.
Several studies on breast cancer assessed classifiers predic-
tive of survival [60-65]. A Dutch group reported 70 genes
predictive of disease recurrence in women with lymph-
node-negative primary breast cancer and confirmed the
findings in a second study comprising additional 198
patients [65]. This study could assign some women to a
Confirmation of expression measurements by real-time RT-PCR Independent clustering of the qPCR data for both, Affymetrix  and TaqMan platforms resulted in similar correlation trees Figure 5
Confirmation of expression measurements by real-time RT-PCR Independent clustering of the qPCR data for both, Affymetrix 
and TaqMan platforms resulted in similar correlation trees.
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low-risk category beyond the discriminating power of
conventional histopathological criteria.
However, the concordance among different studies on
survival of breast cancer patients is low. Data inconsist-
ency can be particularly explained by the use of different
microarray technologies and different patients' demo-
graphics. In addition, subtleties in data analysis may
explain some discrepancies since there is no standardize
method for expression data analysis when a large number
of data points per individual are studied in relatively low
sample populations.
In this study, we accurately discriminated samples that
had a high tumor content from normal breast tissue based
on the previous demonstration that FHL1 and CLDN5 can
serve as such predictors. Then, we identified predictors in
cancer tissues from primary tumors by identifying genes
capable of segregating two distinct classes of tumors
according to response to treatment (pCR vs NC). "Favora-
ble outcome signature" could predict complete remission
of a primary tumor with >90% sensitivity. Some genes
found to be highly expressed in pCR samples belong to
the "biological topic" of mitosis and cell proliferation (e.g.
MAD2L1, CCNB2). This is concordant with the observa-
tions we [59] and others made on the ki-67 expression
and the negative ER status in responding tumors [66].
Possibly, actively dividing tumors, either driven by the
lack of hormonal control or by other signals such as via
the insulin receptor pathway may respond best. The "poor
outcome signature" distinguishing tumors unlikely to
respond to PST included DDB2 or XPA, involved in DNA
damage repair which makes perfect logical sense. The
highest predictive value was sought in a stepwise manner
by comparing pCR to NC cases and comparing predictors
of each group by multi-step statistical approaches and k-
NN (k = 3) validation. This classifier could predict with a
remarkable level of accuracy a pathological response in
the subsequent cohort of 27 patients used for validation.
It is also possible that there were mis-assignments of
responding cases especially in borderline cases that
responded with minor changes in size or bifocal tumors.
Ultra-sound imaging applied for size determination prior
to chemotherapy might not be comparable to the accurate
measurements that pathologists can make on resected
samples. Thus, 10 cases in the training set considered as
PR might not have qualified if comparable measurements
could be used before and after therapy. This undefined
error might have partially affect our statistical analysis
decreasing the sensitivity of the model adopted (i.e., pre-
dict many NC cases as PR and vice versa).
We also observed that application of different statistical
algorithms to the data analysis lead to the extraction of
overlapping predictor signatures (19 of 57 genes were in
common). Although some of the genes identified by the
PLS-DA could have been dismissed by the stringent filter-
ing criteria applied, both analytical approaches could
predict pCR. Accuracy of NC prediction could only be
achieve through the stepwise identified signatures. Fur-
ther in depth interpretation of the biological processes
associated with the genes identified statistically will prob-
ably enhance the robustness of our findings in the future
[67-69] [70].
We attempted to override the risk of overfitting of the
model based on the training data (i.e., finding a mass of
less relevant genes that may lead to the loss of a few rele-
vant ones). The prediction accuracy was relatively high
but was limited by the number of validation events (pCR
or NC) so far analyzed suggesting that improved selection
predictor genes among the ones identified based on a
larger validation study may increase the accuracy of our
findings and as a consequence their clinical value. We are
currently collecting samples for a second validation
cohort receiving EC based PST under similar conditions at
an independent institution.
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